Jazz Pharma's JZP-110 successful in two late-stage studies in obstructive sleep apnea; shares up 6%

|About: Jazz Pharmaceuticals, ... (JAZZ)|By:, SA News Editor

Jazz Pharmaceuticals (JAZZ +6.1%) perks up on increased volume in response to its announcement of positive results from two Phase 3 trials assessing Orphan Drug-tagged JZP-110, a selective dopamine and norepinephrine reuptake inhibitor, for the treatment of excessive sleepiness in adults with obstructive sleep apnea (OSA).

Both studies, TONES 3 and TONES 4, met their co-primary endpoints.

Results from TONES 2, assessing JZP-110 for the treatment of excessive sleepiness associated with narcolepsy, should be available next quarter. An NDA is on tap for Q4.

Previously: Patient enrollment complete in Jazz Pharma's late-stage studies of excessive sleepiness candidate JZP-110, top-line data expected in Q1 2017 (Sept. 26, 2016)